House Re­pub­li­cans use FDA ap­pro­pri­a­tions bill to over­ride REMS changes on abor­tion pill

The Re­pub­li­can-led House Ap­pro­pri­a­tions Com­mit­tee on Wednes­day ad­vanced the 2024 FDA spend­ing bill by a 34-27 vote af­ter De­moc­rats failed to re­move lan­guage in the bill that would nul­li­fy changes the FDA made to the risk eval­u­a­tion and mit­i­ga­tion strat­e­gy (REMS) for the abor­tion pill mifepri­s­tone in Jan­u­ary.

Those FDA changes had eased ac­cess to mifepri­s­tone by al­low­ing cer­tain phar­ma­cies to dis­pense the pill, which is used in com­bi­na­tion with an­oth­er med­i­cine to end ear­ly preg­nan­cies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA